Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.24)
# 3,380
Out of 4,829 analysts
29
Total ratings
40%
Success rate
-13.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.61 | +211.53% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $184.60 | +11.05% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $6.15 | +273.98% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.19 | +404.20% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $549.27 | +28.53% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $36.27 | +368.71% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $4.52 | +1,338.05% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.20 | +376.19% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $132.18 | +55.85% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $44.27 | +49.09% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.26 | +1,646.03% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $1.47 | +580.27% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $11.18 | +436.91% | 1 | Oct 5, 2022 |
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.61
Upside: +211.53%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $184.60
Upside: +11.05%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $6.15
Upside: +273.98%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.19
Upside: +404.20%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $549.27
Upside: +28.53%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $36.27
Upside: +368.71%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $4.52
Upside: +1,338.05%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.20
Upside: +376.19%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $132.18
Upside: +55.85%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $44.27
Upside: +49.09%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.26
Upside: +1,646.03%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.47
Upside: +580.27%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $11.18
Upside: +436.91%